Treatment Strategies in Myelodysplastic Syndromes

By Atallah Ehab   Garcia-Manero Guillermo  

Cancer Investigation, Vol. 26, Iss. 2, 2008-02 ,pp. : 208-216

Informa Healthcare

Access to resources Recommend Favorite

PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes

By Qin Ya-Zhen   Zhu Hong-Hu   Liu Yan-Rong   Wang Ya-Zhe   Shi Hong-Xia   Lai Yue-Yun   Xu Lan-Ping   Liu Dai-Hong   Jiang Qian   Li Ling-Di   Jiang Bin   Liu Kai-Yan   Huang Xiao-Jun  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1442-1449

Informa Healthcare

Access to resources Recommend Favorite

Pathology of the Future: Molecular Profiling for Targeted Therapy

By Espina Virginia   Geho David   Mehta Arpita   Petricoin Emanuel   Liotta Lance   Rosenblatt Kevin  

Cancer Investigation, Vol. 23, Iss. 1, 2005-02 ,pp. : 36-46

Informa Healthcare

Access to resources Recommend Favorite

Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy

By Smith B. Douglas   Mahmoud Dalia   Dacosta-Byfield Stacey   Rosen Virginia M.  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1119-1125

Informa Healthcare

Access to resources Recommend Favorite

Myelofibrosis in primary myelodysplastic syndromes: Clinical and Biological Significance

By Marisavljević D.   Rolović Z.   Ćemerikić V.   Bošković D.   Ćolović M.  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 325-331

Humana Press, Inc

Access to resources Recommend Favorite